About Veriskin
Veriskin is a company based in San Diego (United States) founded in 2014. Veriskin has raised $1.68 million across 5 funding rounds from investors including HHS, National Cancer Institute and Pasadena Angels. Veriskin offers products and services including TruScore Device. Veriskin operates in a competitive market with competitors including Castle Biosciences, DermTech, AMLo Biosciences, Haut and MELAGENIX, among others.
- Headquarter San Diego, United States
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
- Legal Name Veriskin, Inc
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$1.68 M (USD)
in 5 rounds
-
Latest Funding Round
$3.9 M (USD), Grant
May 24, 2021
-
Investors
HHS
& 5 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Veriskin
Veriskin offers a comprehensive portfolio of products and services, including TruScore Device.
Handheld tool for non-invasive, real-time skin cancer screening.
People of Veriskin
Unlock access to complete
Unlock access to complete
Unlock access to complete
Funding Insights of Veriskin
Veriskin has successfully raised a total of $1.68M across 5 strategic funding rounds. The most recent funding activity was a Grant round of $3.9 million completed in May 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Veriskin
Veriskin has secured backing from 6 investors, including venture fund and institutional investors. Prominent investors backing the company include HHS, National Cancer Institute and Pasadena Angels.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Investments are facilitated by Pasadena Angels in Southern California startups.
|
Locked | Locked | Locked | |
|
A Montana-based network of angel investors is operated.
|
Locked | Locked | Locked | |
|
Angel investments are made in startups across various sectors.
|
Locked | Locked | Locked |
Investor details for Veriskin
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Veriskin
Investment portfolio details for Veriskin
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Veriskin
Detailed financials for Veriskin
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Veriskin Comparisons
Peer comparison for Veriskin
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Veriskin
Veriskin operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Castle Biosciences, DermTech, AMLo Biosciences, Haut and MELAGENIX, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Precision diagnostic and prognostic tests are developed by Castle Biosciences.
|
|
| Locked | Locked | Locked |
Adhesive patch biopsies for skin cancer detection are provided.
|
|
| Locked | Locked | Locked |
Prognostic tests for early-stage melanoma detection are developed.
|
|
| Locked | Locked | Locked |
SaaS solutions using AI for skincare businesses are provided.
|
|
| Locked | Locked | Locked |
Molecular diagnostic tests for skin cancer detection are developed.
|
Detailed competitors of Veriskin
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Veriskin
Complete news archive for Veriskin
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Veriskin
Veriskin was founded in 2014 and raised its 1st funding round 2 years after it was founded.
Veriskin is headquartered in San Diego, United States. It is registered at San Diego, California, United States.
Veriskin is a funded company, having raised a total of $1.68M across 5 funding rounds to date.
Veriskin was founded in 2014 in San Diego, United States, and operates in the medical technology sector. Non-invasive diagnostic tools for skin cancer are developed by the company, including a device that employs spectroscopy to assess pressure-induced hemodynamic variations between benign and malignant lesions. Investigations focus on applications for basal-cell carcinoma and squamous cell carcinoma, with operations centered on advancing these diagnostic technologies.
Veriskin's top competitors include DermTech, AMLo Biosciences and Castle Biosciences.
Veriskin offers TruScore Device.
Veriskin has 6 investors. Key investors include HHS, National Cancer Institute, Pasadena Angels, Frontier Angels, and Ariel Savannah Angel Partners.